Mortality in critically ill COVID-19 patients with fungal infections: a comprehensive systematic review and meta-analysis

Krzych, Łukasz J.; Putowski, Zbigniew; Gruca, Karol; Pluta, Michał

doi:10.20452/pamw.16221

Cited by 7 publications

(5 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bacterial and fungal infections are well-known complications of COVID-19 and are significantly associated with poor prognosis [ [134] , [135] , [136] , [137] , [138] , [139] , [140] , [141] ]. A pooled study containing 171 trials with 171,262 patients with COVID-19 discovered that the prevalence of combined bacterial infections was 5.1%, and secondary bacterial infections were 13.1%.…”

Section: Resultsmentioning

confidence: 99%

Xuanfei Baidu decoction in the treatment of coronavirus disease 2019 (COVID-19): Efficacy and potential mechanisms

Meng,

Ding,

Shen

et al. 2023

Heliyon

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Xuanfei Baidu decoction in the treatment of coronavirus disease 2019 (COVID-19): Efficacy and potential mechanisms

Meng,

Ding,

Shen

et al. 2023

Heliyon

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…Patients hospitalized in an ICU with severe COVID-19 are at increased risk of developing secondary infections, such as invasive fungal infections [ 63 , 64 ]. This is because they have underlying medical conditions, such as chronic respiratory diseases, and are often treated with corticosteroid therapy and intubation/mechanical ventilation [ 63 , 64 ]. Although there are many reasons for death in critically ill patients with COVID-19, the role of co-infections and their significance are not well understood, with limited research done in this area.…”

Section: Discussionmentioning

confidence: 99%

Mortality in ICU Patients with COVID-19-Associated Pulmonary Aspergillosis

Beltrame

Stevens

Haiduven

2023

JoF

View full text Add to dashboard Cite

A review of 38 studies involving 1437 COVID-19 patients admitted to intensive care units (ICUs) with pulmonary aspergillosis (CAPA) was conducted to investigate whether mortality has improved since the pandemic’s onset. The study found that the median ICU mortality was 56.8%, ranging from 30% to 91.8%. These rates were higher for patients admitted during 2020–2021 (61.4%) compared to 2020 (52.3%), and prospective studies found higher ICU mortality (64.7%) than retrospective ones (56.4%). The studies were conducted in various countries and used different criteria to define CAPA. The percentage of patients who received antifungal therapy varied across studies. These results indicate that the mortality rate among CAPA patients is a growing concern, mainly since there has been an overall reduction in mortality among COVID-19 patients. Urgent action is needed to improve prevention and management strategies for CAPA, and additional research is needed to identify optimal treatment strategies to reduce mortality rates among these patients. This study serves as a call to action for healthcare professionals and policymakers to prioritize CAPA, a serious and potentially life-threatening complication of COVID-19.

show abstract

“…The fatality rate in our research is up to 76.5% and is higher than that reported in the literature. A comprehensive systematic review and meta-analysis found that critically ill patients with CAPA have severely increased mortality, with a median of 54% (IQR 36–70%) in the suspected CAPA group [ 50 ]. In various studies, the mortality ranged from 44.5 to 66.7% to even 100% [ 49 , 51 ].…”

Section: Discussionmentioning

confidence: 99%

COVID-19-Associated Pulmonary Aspergillosis in Intensive Care Unit Patients from Poland

Skóra

Gajda

Namysł³

et al. 2023

JoF

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) has been shown to be a favoring factor for aspergillosis, especially in a severe course requiring admission to the intensive care unit (ICU). The aim of the study was to assess the morbidity of CAPA among ICU patients in Poland and to analyze applied diagnostic and therapeutic procedures. Medical documentation of patients hospitalized at the temporary COVID-19 dedicated ICU of the University Hospital in Krakow, Poland, from May 2021 to January 2022 was analyzed. In the analyzed period, 17 cases of CAPA were reported with an incidence density rate of 9 per 10 000 patient days and an incidence rate of 1%. Aspergillus fumigatus and Aspergillus niger were isolated from lower respiratory samples. Antifungal therapy was administered to 9 patients (52.9%). Seven patients (77.8%) received voriconazole. The CAPA fatality case rate was 76.5%. The results of the study indicate the need to increase the awareness of medical staff about the possibility of fungal co-infections in ICU patients with COVID-19 and to use the available diagnostic and therapeutic tools more effectively.

show abstract

Mortality in critically ill COVID-19 patients with fungal infections: a comprehensive systematic review and meta-analysis

Cited by 7 publications

References 45 publications

Xuanfei Baidu decoction in the treatment of coronavirus disease 2019 (COVID-19): Efficacy and potential mechanisms

Xuanfei Baidu decoction in the treatment of coronavirus disease 2019 (COVID-19): Efficacy and potential mechanisms

Mortality in ICU Patients with COVID-19-Associated Pulmonary Aspergillosis

COVID-19-Associated Pulmonary Aspergillosis in Intensive Care Unit Patients from Poland

Contact Info

Product

Resources

About